Sara Figueiredo

Sara Figueiredo

Auto-generated profile, based on publicly available information

Sara Figueiredo

Nanomedicine@FCT, CIGMH (Centro de Investigação em Genética Molecular Humana), UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus da Caparica, Caparica, Portugal

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
SFSara Figueiredo
Sara Figueiredo
João Nuno MoreiraJoão Nuno Moreira
João Nuno Moreira
Carlos F.G.C. GeraldesCarlos F.G.C. Geraldes
Carlos F.G.C. Geraldes
SRSilvia Rizzitelli
Silvia Rizzitelli
SASilvio Aime
Silvio Aime
ETEnzo Terreno
Enzo Terreno
This communication demonstrates that yeast cell wall particles (YCWPs) are a promising class of nature-inspired biocompatible microcarriers for the delivery of amphipathic/lipophilic imaging reporters. When a paramagnetic MRI agent is loaded, the longitudinal relaxivity per particle at 0.5 T is the highest ever reported for Gd-based systems.

1 January 2014
Verified
Book Chapter
Closed access
Miguel Peixoto de AlmeidaMiguel Peixoto de Almeida
Miguel Peixoto de Almeida
EPEulalia Pereira
Eulalia Pereira
PBPedro Baptista
Pedro Baptista
IGInês Gomes
Inês Gomes
SFSara Figueiredo
Sara Figueiredo
Ricardo FrancoRicardo Franco
Ricardo Franco

1 May 2015 in Nanobiosensors in Disease Diagnosis
Verified
Journal Article
Open access
PDF file
PBPedro V Baptista
Pedro V Baptista
Alexandra FernandesAlexandra Fernandes
Alexandra Fernandes
SFSara Figueiredo
Sara Figueiredo
RVRaquel Vinhas
Raquel Vinhas
MCMilton Cordeiro
Milton Cordeiro
SMSoraia Mendo
Soraia Mendo
Nanotheranostics takes advantage of nanotechnology-based systems in order to diagnose and treat a specific disease. This approach is particularly relevant for personalized medicine, allowing the detection of a disease at an early stage, to direct a suitable therapy toward the target tissue based on the molecular profile of the altered phenotype, subsequently facilitating disease monitoring and following treatment. A tailored strategy also enables to reduce the off-target effects associated with universal treatments and improve the safety profile of a given treatment. The unique optical properties of gold nanoparticles, their ease of surface modification, and high surface-to-volume ratio have made them central players in this area. By combining imaging, targeting, and therapeutic agents in a single vehicle, these nanoconjugates are (ought to be) an important tool in the clinics. In this review, the multifunctionality of gold nanoparticles as theranostics agents will be highlighted, as well as the requirements before the translation of these nanoplatforms into routine clinical practice.

21 November 2012 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
SFSara Figueiredo
Sara Figueiredo
JCJuan Carlos Cutrin
Juan Carlos Cutrin
SRSilvia Rizzitelli
Silvia Rizzitelli
ELElisa De Luca
Elisa De Luca
João Nuno MoreiraJoão Nuno Moreira
João Nuno Moreira
ETEnzo Terreno
Enzo Terreno
Purpose This study is aimed at demonstrating the in vivo potential of Gd(III)-loaded glucan particles (Gd-GPs) as magnetic resonance imaging (MRI)-positive agents for labeling and tracking phagocytic cells. Procedure GPs were obtained from Saccharomyces cerevisae and loaded with the water-insoluble complex Gd-DOTAMA(C18)2. The uptake kinetics of Gd-GPs by murine macrophages was studied in vitro and the internalization mechanism was assessed by competition assays. The in vivo performance of Gd-GPs was tested at 7.05 T on a mouse model of acute liver inflammation. Results The minimum number of Gd-GPs-labeled J774.A1 macrophages detected in vitro by MRI was ca. 300 cells/μl of agar, which is the lowest number ever reported for cells labeled with a positive T1 agent. Intravenous injection of macrophages labeled with Gd-GPs in a mouse model of liver inflammation enabled the MRI visualization of the cellular infiltration in the diseased area. Conclusions Gd-GPs represent a promising platform for tracking macrophages by MRI as a T1 alternative to the golden standard T2-based iron oxide particles.

1 February 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SFSara Figueiredo
Sara Figueiredo
João Nuno MoreiraJoão Nuno Moreira
João Nuno Moreira
Carlos F.G.C. GeraldesCarlos F.G.C. Geraldes
Carlos F.G.C. Geraldes
SASilvio Aime
Silvio Aime
ETEnzo Terreno
Enzo Terreno

3 April 2015 in RSC Advances
Verified
Journal Article
Open access
PDF file
FGFrancesca Garello
Francesca Garello
FAFrancesca Arena
Francesca Arena
JCJuan Carlos Cutrin
Juan Carlos Cutrin
GEGiovanna Esposito
Giovanna Esposito
LDLuca D'ANgeli
Luca D'ANgeli
ETEnzo Terreno
Enzo Terreno
Glucan Particles (GPs) are hollow pseudo-microspheres (average diameter 3–5 μm) obtained from common baker's yeast Saccharomyces cerevisiae, in which mannan, lipids and proteins are removed through a process of chemical extraction. GPs shell is mostly made of 1,3-β-D-glucan that allows for their prompt in vivo uptake by immune system cells. In this work, the inner cavity of the particles has been loaded with two amphiphilic fluorescent dyes (based on cyanine for in vivo imaging purposes and rhodamine for ex vivo microscopy experiments) through a sudden change in solvent polarity that allowed the entrapment of the molecules as microemulsion. The ability of fluorescent GPs to label immune cells in vivo and report on their recruitment in inflamed sites has been successfully demonstrated in a mouse model of rheumatoid arthritis (CIA) by NIRF imaging. Besides providing the visualization of the mononuclear cell infiltration in the lesion, the fluorescent signal well correlated with the clinical score associated with the disease. Very interestingly, the signal detected in lesions with the same clinical score allowed the assessment of the time evolution (progression or remission) of the pathology.